HUTCHMED (China) Limited (HCM)
- Previous Close
16.45 - Open
16.34 - Bid 16.33 x 200
- Ask 16.45 x 100
- Day's Range
16.07 - 16.53 - 52 Week Range
10.68 - 20.73 - Volume
186,785 - Avg. Volume
137,170 - Market Cap (intraday)
2.832B - Beta (5Y Monthly) 0.68
- PE Ratio (TTM)
27.27 - EPS (TTM)
0.60 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
28.47
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
www.hutch-med.com1,988
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: HCM
Performance Overview: HCM
Trailing total returns as of 4/18/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: HCM
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: HCM
Valuation Measures
Market Cap
2.86B
Enterprise Value
2.06B
Trailing P/E
27.27
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.39
Price/Book (mrq)
3.82
Enterprise Value/Revenue
2.46
Enterprise Value/EBITDA
30.69
Financial Highlights
Profitability and Income Statement
Profit Margin
12.03%
Return on Assets (ttm)
0.99%
Return on Equity (ttm)
14.65%
Revenue (ttm)
838M
Net Income Avi to Common (ttm)
100.78M
Diluted EPS (ttm)
0.60
Balance Sheet and Cash Flow
Total Cash (mrq)
889.01M
Total Debt/Equity (mrq)
11.59%
Levered Free Cash Flow (ttm)
39.68M
Research Analysis: HCM
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell